Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: Five-year results of a randomized controlled trial  by Klinkert, Pieter et al.
Vein versus polytetrafluoroethylene in above-knee
femoropopliteal bypass grafting: Five-year results
of a randomized controlled trial
Pieter Klinkert, MD,a Abbey Schepers, MD,a Desire´e H. C. Burger, MD,a J. Hajo van Bockel, MD, PhD,b
and Paul J. Breslau, MD, PhD,a The Hague and Leiden, The Netherlands
Objective: Controversy still exists whether polytetrafluoroethylene is equivalent to vein as bypass graft material for the
above-knee femoropopliteal bypass. Therefore, a prospective randomized trial was performed to compare vein with
polytetrafluoroethylene for femoropopliteal bypasses with the distal anastomosis above the knee.
Methods: Between January 1993 and December 1996, 151 above-knee femoropopliteal bypasses were performed. The
indications for operation were severe claudication in 120 cases, rest pain in 20 cases, and ulceration in 11 cases. After
randomization, 75 reversed saphenous venous bypasses and 76 polytetrafluoroethylene bypasses were performed.
Results: No perioperative mortality was seen, and 5% of the patients had minor infections of the wound, not resulting in
loss of the bypass, the limb, or life. After 5 years, 38% of the patients had died and 7% were lost to follow-up. Only once
was the saphenous vein necessary for coronary artery bypass grafting. Primary patency rates after 5 years were 75.6% for
venous bypass grafts and 51.9% for polytetrafluoroethylene grafts (P  .035). Secondary patency rates were 79.7% for
vein and 57.2% for polytetrafluoroethylene bypasses (P  .036). In the venous group, 14 bypasses failed, leading to five
new bypasses. In the polytetrafluoroethylene group, 29 bypasses failed, leading to 16 reinterventions. For these 16 new
bypasses, in four cases, the ipsilateral preserved saphenous vein was used. In both groups, one above-knee amputation and
one below-knee amputation had to be performed.
Conclusion: We conclude after 5 years of follow-up of this randomized controlled trial that a bypass with saphenous vein
has better patency rates at all intervals and needs fewer reoperations. Saphenous vein should be the graft material of choice
for above-knee femoropopliteal bypasses and should not be preserved for reinterventions. Polytetrafluoroethylene is an
acceptable alternative if the saphenous vein is not available. (J Vasc Surg 2003;37:149-55.)
That autologous saphenous vein is the material of
choice for a femoropoplitial bypass below the knee is gen-
erally accepted.1-5 For the femoropopliteal bypass with the
distal anastomosis above the knee, controversy still exists
whether prosthetic materials like polytetrafluoroethylene,
Dacron, and human umbilical vein are equivalent to autol-
ogous saphenous vein. Studies supporting other materials
than vein for bypass either are not randomized6,7 or do not
compare prosthetic material with vein.8 The only random-
ized controlled trial with a long-term follow-up that was
performed before this study was started compared autolo-
gous saphenous vein and polytetrafluoroethylene for the
above-knee femoropopliteal bypass graft and found no
statistical difference between autologous vein and polytet-
rafluoroethylene after 4 years.5
In 1993, this randomized controlled trial was started in
our institution to answer the following questions: 1, Is
there a difference in cumulative patency rates between
saphenous vein and polytetrafluoroethylene bypass grafts?
2, What are the consequences of bypass failure? and 3, If
polytetrafluoroethylene is used, is the autologous vein still
available and useful for more distal procedures or for coro-
nary artery bypass grafting?
The conclusions, reported after 2 years of follow-up,
were that there was no statistical significant difference in
primary and secondary patency rates between vein and
polytetrafluoroethylene. In the suprageniculate position,
polytetrafluoroethylene could be an acceptable alternative
for femoropopliteal bypass grafting in above-knee proce-
dures, especially in patients with a short life expectancy.
There was minimal use of preserved veins for other bypass
procedures. However, the follow-up period was only 2 years.9
Since the start of this study, two randomized trials
comparing vein with polytetrafluoroethylene were pub-
lished. AbuRahma, Robinson, and Holt10 found no differ-
ence in primary patency rates after 6 years. However, John-
son and Lee11 reported significant better primary patency
rates for vein than for polytetrafluoroethylene after 5 years.
This study reports the results of our prospective random-
ized trial with a 5-year follow-up period.
PATIENTS AND METHODS
Patients who underwent a femoropopliteal bypass op-
eration with the distal anastomosis to the popliteal artery
above the knee between January 1993 and December 1996
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were eligible for this study. Included were all patients with
disabling claudication, rest pain, or tissue-loss who under-
went arterial reconstruction. Excluded were patients with
an earlier arterial bypass graft procedure in the same leg or
with the greater saphenous vein removed earlier.
History was obtained from every patient and included
previous operations and risk factors for arterial occlusive
disease (diabetes, smoking, cerebrovascular accidents, and
cardiac history). In every patient, a hemodynamic profile
was obtained, comprising the ankle blood pressures and a
velocity profile of the common femoral, popliteal, and
distal arteries at the level of the ankle. Also, an arteriogram
was obtained with the translumbar route or transfemoral
with the Seldinger technique. The popliteal and tibial ar-
teries were scored in terms of open or occluded to grade the
runoff.12 The Institutional Review Board of the Red Cross
Hospital, The Hague, approved the study protocol. Patient
consent was obtained in all cases.
Before the operation, all patients received 1 g of cefa-
mandole intravenously. Patients underwent operation with
general or regional anesthesia. The operating surgeon in-
spected the popliteal artery and the saphenous vein. Above-
knee grafting was performed when the above-knee popli-
teal artery was patent and suitable for anastomosis during
the operation. When the quality of the greater saphenous
vein was suitable for bypass grafting (ie, with a diameter of
more than 4 mm proximally and 3 mm distally), random-
ization took place with closed envelope allocation. Either
the reversed vein or a stretched thin-walled 6-mm polytet-
rafluoroethylene (W. L. Gore, Flagstaff, Ariz) prosthesis
was used. Before clamping, heparin was given intravenously
in a dose of 5000 international units. All anastomoses were
made end-to-side with continuous 6-0 prolene sutures,
proximal to the common femoral artery and distal to the
popliteal artery.
Oral coumarin (Sintrom, Ciba-Geigy) was started the
day before the operation and was continued for 6 months,
with aim for an international normalized ratio between 2
and 4. After 6 months, 38 mg acetylsalicylic acid was given
daily.
Follow-up visits were carried out at discharge and
thereafter at 6 weeks, 3 months, 6 months, and 1 year and
every following year. Examination comprised a history, a
physical examination, and a hemodynamic profile. Graft
occlusion was determined with a drop in distal blood
pressure of more than 20% compared with a previous visit
and a velocity profile consistent with collateral flow in the
distal popliteal artery. If a polytetrafluoroethylene bypass
occluded and the occlusion was detected within 7 days, a
thrombectomy was performed. In all other cases, a policy of
“wait and see” was followed if the patient had mild claudi-
cation develop. In cases of rest pain or necrosis, a redo
bypass procedure was performed.
The primary endpoint of the study was the patency of
the bypass at the end of the fifth year. Patients could be
included in the study twice for primary operation on either
the left or the right limb. Analysis of the primary endpoint
was performed per limb.
Primary patency was considered to be uninterrupted
patency with no procedures performed on the bypass or the
adjacent native vessel. Secondary patency was the patency
after restoration of an occlusion or after a procedure to
protect the bypass from occluding. Most of the original
bypass and at least one of the anastomosis must have been
retained in continuity.12
Cumulative patency rates were calculated with life-
table analysis and compared with the log-rank test. Student
t test was used to compare the patient characteristics.
Differences in reinterventions were calculated with the 2
test.
RESULTS
Randomization took place in 151 bypass graft opera-
tions in 136 patients between January 1993 and December
1996. The risk factors and angiographic results were
equally divided between those who received a venous by-
pass graft and those who received a polytetrafluoroethylene
bypass graft, except for diabetes mellitus, which was signif-
icant lower in the venous group (Table I).
Reversed vein was used in 75 bypass grafts, and 6-mm
stretched polytetrafluoroethylene prostheses were used 76
times. Bilateral reconstruction was done in 15 patients. Five
patients received polytetrafluoroethylene bypass grafts in
both limbs, two with only venous bypass grafts, and eight
patients received polytetrafluoroethylene in one limb and
vein in the other.
The operating time from skin incision until skin closure
was significantly longer in venous bypasses (mean, 105
minutes) than in polytetrafluoroethylene grafts (mean, 73
minutes; P .002). A superficial wound infection was seen
in seven cases (three times with a polytetrafluoroethylene
and four times with a venous bypass). None of these
infections resulted in reoperation or loss of the bypass.
None of the patients died in the hospital or within 30 days
after the operation.
After 5 years, 57 patients had died (38%); 42 with an
open and 15 with an occluded bypass. Eleven patients were
lost to follow-up (7%).
Primary patency rates after 5 years were 75.6% for
venous bypass grafts and 51.9% for polytetrafluoroethylene
grafts (P  .035; Tables II and III; Fig 1). Secondary
patency rates were 79.7% for vein and 57.2% for polytetra-
fluoroethylene (P  .036; Tables IV and V; Fig 2).
In the venous bypass group, 14 bypasses failed. In nine
patients, we did not perform a reintervention because the
patient only had mild claudication. Five new bypass opera-
tions were performed: in three cases, a new polytetrafluo-
roethylene bypass was made above the knee; in one case,
the venous bypass was extended with vein to below the
knee; and in one case, a human umbilical vein (Dardik
Biografts, Bio-Vascular, Inc, St Paul, Minn) was used for a
femoroinfrapopliteal bypass. Failure of two of these redo
bypasses led to two polytetrafluoroethylene femorotibial
bypasses but finally an occlusion and an amputation (one
above-knee and one below-knee). In this group, one coro-
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nary bypass operation was performed with the distal saphe-
nous vein from the ipsilateral side as the graft material.
In the polytetrafluoroethylene group, 29 bypasses
failed. Thirteen times, no reinterventions were planned
because the patients only had mild claudication. Because of
severe claudication or rest pain, three times a new bypass
above the knee was performed, all with polytetrafluoroeth-
ylene. Twelve bypasses had to be performed below the
knee: in eight cases, these were polytetrafluoroethylene
bypasses; in one case, human umbilical vein; and in three
cases, saphenous vein. One venous femorotibial bypass was
constructed. There were significantly more reinterventions
because of a failing polytetrafluoroethylene bypass graft
compared with failing venous bypasses (P .011). Because
of failed reinterventions, three patients received a polytet-
rafluoroethylene femorotibial bypass. Two amputations
had to be performed (one above-knee and one below-
knee). In this group, two coronary bypass reconstructions
were performed, but no bypass was constructed of saphe-
nous vein.
Table I. Patient characteristics from included patients
Total Vein PTFE P value
Reconstructions 151 75 76
Median age (y) 69 70 68 .10
Male gender 88 42 46 .28
Risk factors
Smoking 105 48 57 .07
Diabetes mellitus 33 12 21 .04
Cardiac history 31 15 16 .44
Cerebrovascular accident 7 5 2 .12
Indication .49
Claudication 120 62 58
Rest pain 20 9 11
Necrosis 11 4 7
Open tibial arteries .49
3 80 43 37
2 47 21 26
1 24 11 13
PTFE, Polytetrafluoroethylene.
Table II. Life-table analysis of primary patency rate of autologous saphenous vein
Interval At risk Occluded Died LFU
Cumulative
patency rate SEM
0-6 wk 75 5 1 1 93.3% 2.9
6-12 wk 68 2 1 1 90.6% 3.4
12-26 wk 64 4 3 0 84.9% 4.2
26-52 wk 57 3 3 0 80.5% 4.7
1-2 y 51 3 2 2 77.3% 5.0
2-3 y 44 1 5 3 75.6% 5.2
3-4 y 35 0 7 0 75.6% 5.2
4-5 y 28 0 2 1 75.6% 5.2
LFU, Lost to follow-up; SEM, standard error of mean.
Table III. Life-table analysis of primary patency rate of polytetrafluoroethylene
Interval At risk Occluded Died LFU
Cumulative
patency rate SEM
0-6 wk 76 3 0 0 96.1% 2.2
6-12 wk 73 3 0 0 92.1% 3.1
12-26 wk 70 5 1 0 85.5% 4.0
26-52 wk 64 5 4 0 78.9% 4.7
1-2 y 55 6 2 0 68.8% 5.4
2-3 y 47 5 4 1 61.3% 5.8
3-4 y 37 2 5 0 57.9% 5.9
4-5 y 30 3 2 1 51.9% 6.2
LFU, Lost to follow-up; SEM, standard error of mean.
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Primary patency rates were related to the outflow. After
5 years, the patency rates were 63.3% in the group with
three open crural arteries, 57.6% with two open arteries,
and 70.4% with one open artery (P  .50; Table VI).
DISCUSSION
The question of the best material for above-knee bypass
graft surgery, polytetrafluoroethylene or saphenous vein,
Fig 1. Primary patency rates over time comparing vein with polytetrafluoroethylene in above-knee femoropopliteal
bypass. Error bars are standard error of mean.
Table IV. Life-table analysis of secondary patency rate of autologous saphenous vein
Interval At risk Occluded Died LFU
Cumulative
patency rate SEM
0-6 wk 75 4 1 1 94.7% 2.6
6-12 wk 69 1 1 1 93.3% 2.9
12-26 wk 66 3 3 0 89.1% 3.7
26-52 wk 60 2 3 0 85.5% 4.1
1-2 y 55 3 2 2 81.4% 4.7
2-3 y 48 1 5 4 79.7% 4.9
3-4 y 38 0 7 0 79.7% 4.9
4-5 y 31 0 2 0 79.7% 4.9
LFU, Lost to follow-up; SEM, standard error of mean.
Table V. Life-table analysis of secondary patency rate of polytetrafluoroethylene
Interval At risk Occluded Died LFU
Cumulative
patency rate SEM
0-6 wk 76 2 0 0 97.4% 1.8
6-12 wk 74 3 0 0 93.4% 2.8
12-26 wk 71 4 1 0 88.2% 3.7
26-52 wk 66 2 4 0 85.5% 4.0
1-2 y 60 6 2 0 76.9% 4.9
2-3 y 52 5 3 2 69.5% 5.4
3-4 y 42 4 5 0 62.9% 5.8
4-5 y 33 3 3 1 57.2% 6.2
LFU, Lost to follow-up; SEM, standard error of mean.
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was once controversial. Our randomized controlled trial
was one of the few that was started to answer this question.
The problem with many of these randomized trials, includ-
ing our own, was that patient recruitment proved to be
difficult, resulting in deficient power for conclusion. Our
conclusion after 2 years of follow-up was that polytetrafluo-
roethylene was a reasonable alternative but that long-term
results should be awaited. Another problem is that fol-
low-up is often deficient.13,14 With respect to follow-up,
we were successful in seeing all but seven of our patients in
the outpatient clinic. After 5 years of follow-up, we found a
significant difference in primary patency rates of 75.6% for
vein and 51.9% for polytetrafluoroethylene (P .035). The
secondary patency rates were 79.7% and 57.2%, respectively
(P  .036).
In Table VII, our results are compared with the three
other published randomized trials.5,10,11 The difference
between the four studies is that in the series of Veith et al5
and Johnson and Lee,11 87% and 72%, respectively, of the
patients had severe ischemia (rest pain or necrosis). This
differs from our series (24%) and the series of AbuRahma,
Robinson, and Holt10 (0). It can be expected that the
outflow in patients with severe ischemia is poor compared
with those with claudication. This might explain the less
favorable long-term patency rates described by Veith et al5
and Johnson and Lee11 (38% and 39%, respectively).
Michaels15 estimated that 160 grafts are required in the
two randomized groups to have a 95% chance of showing
significance (P  .05), assuming that there is a 20% differ-
ence in 5-year patency rates. Despite the fact that we did
not include that many patients, we found a statistical dif-
ference in favor of venous graft material. Johnson and Lee11
presented the only other trial with a statistically significant
difference between vein and polytetrafluoroethylene. They
Fig 2. Secondary patency rates over time comparing vein with polytetrafluoroethylene in above-knee femoropopliteal
bypass. Error bars are standard error of mean.
Table VI. Primary patency after 5 years compared with number of patent tibial arteries with preoperative arteriography
(P  .50)
Interval
Three open
arteries SEM
Two open
arteries SEM
One open
artery SEM
0-6 wk 97.4 1.8 92.0 3.8 92.0 5.4
6-12 wk 94.7 2.6 90.0 4.2 84.0 7.3
12-26 wk 85.2 4.1 85.8 5.0 84.0 7.3
26-52 wk 78.2 4.8 81.5 5.6 79.8 8.1
1-2 y 73.9 5.2 69.9 6.8 75.1 8.9
2-3 y 69.2 5.5 64.9 7.2 70.4 9.5
3-4 y 67.4 5.6 61.5 7.6 70.4 9.5
4-5 y 63.3 6.0 57.6 8.0 70.4 9.5
SEM, Standard error of mean.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 1 Klinkert et al 153
included 226 patients in the venous group and 265 in the
polytetrafluoroethylene group. If we compare the patency
rates for vein and polytetrafluoroethylene in all four ran-
domized trials, we see at all intervals a better primary
patency rate for vein.5,9-11 It was shown in a critical review
as well that if saphenous vein is available, a venous bypass
should be chosen.15 When the saphenous vein is absent or
not suitable for bypass grafting, polytetrafluoroethylene is a
good alternative for femoropopliteal bypass material above
the knee.
The only statistically significant risk factor difference
between the two groups was the prevalence of diabetes,
with significantly more patients in the polytetrafluoroeth-
ylene group (P  .04). Evans et al16 and Prendiville et al17
found that diabetes has a negative influence on the patency
of the bypass, whereas others did not find that effect.6,18
Because of the small numbers of patients with risk factors,
no multivariate analysis could be performed. We realize
that because of the small numbers in the subgroups of
patients, a type II statistical error could exist.13
In 14 failing venous bypasses, five patients had critical
ischemia and needed a reoperation. From these five reop-
erations, only two had to be performed below the knee. In
the polytetrafluoroethylene group, 16 reoperations had to
be performed for 29 failing bypass grafts. Thirteen bypasses
had to be placed below the knee. Clearly, less reoperation
had to be performed in the venous group (P  .011). The
fact that in the polytetrafluoroethylene group during reop-
eration the distal anastomosis was more often below the
knee might strengthen the idea that the polytetrafluoroeth-
ylene graft promotes progression of distal atherosclero-
sis.5,7
One of the arguments for use of polytetrafluoroethyl-
ene for the above-knee femoropopliteal bypass graft is
preservation of the vein for a later distal procedure or a
coronary bypass. In the group of 76 polytetrafluoroethyl-
ene bypasses, thus the group in which the vein was pre-
served, 29 graft failures occurred, with necessity for a
venous bypass in only four cases. Two coronary bypasses
were performed with the mammary artery in this patient
group during the follow-up period. In other studies, these
similar conclusions were made.19,20 So, it seems unneces-
sary to save the vein because in case of a failing bypass graft
the spared vein was not used often. Moreover, if the vein
were used for the above-knee bypass, less reoperations had
to be performed below the knee with need for the vein.
When an infrapopliteal bypass or a coronary bypass is
needed, the saphenous vein of the contralateral side is still
available. To save the saphenous vein for coronary bypass
grafts can be argued because of the advancement of cardiac
revascularisation techniques, for example, percutaneous
treatment or the use of the mammary artery.
Finally, four major amputations had to be performed:
two lower leg and two upper leg amputations. In three of
these cases, the indication for the femoropopliteal bypass
was critical ischemia. These results are comparable with the
results described by Johnson and Lee,11 although they
performed more bypasses in patients with critical ischemia.
AbuRahma, Robinson, and Holt10 had no amputations at
all and performed bypasses in patients with claudication
only. Veith et al5 described limb salvage rates of 77% after 4
years but also had many patients with critical ischemia. No
difference was seen between the venous and the polytetra-
fluoroethylene group. Although the use of polytetrafluoro-
ethylene for above-knee bypass did not result in a signifi-
cant increase in major limb amputation rates compared
with use of vein conduits, the patency rates for polytetra-
fluoroethylene were distinctly inferior to those of vein and
significantly more reinterventions were necessary to main-
tain equivalent limb salvages rates in this series consisting
primarily of patients with claudication.
An advantage of polytetrafluoroethylene is the signifi-
cantly shorter operation time. One can consider in patients
with short life expectancy and high operative risk use of
polytetrafluoroethylene as bypass graft material.9
Some authors showed that the runoff (number of
patent tibial arteries) did influence the patency of bypass
grafts.17 We found no significant differences between good
and poor runoff for either venous and polytetrafluoroeth-
ylene bypass grafts. This could be explained either by the
small size of the group or by the relatively proximal site of
the distal anastomosis.
Our conclusion after 2 years of follow-up was that
polytetrafluoroethylene could be safely used for above-knee
femoropopliteal bypass in patients with compromised con-
ditions and in those with short life expectancy. The current
results after 5 years of follow-up show that saphenous vein
has better patency rates at all intervals and needs fewer
reoperations and that saphenous vein should not be spared
for reinterventions. We therefore now prefer the vein as
Table VII. Comparisons of primary patency rates of venous and polytetrafluoroethylene bypass grafts from randomized
controlled trials
Years
Veith et al5 AbuRhama et al10 Johnson and Lee11 This article
Vein PTFE Vein PTFE Vein PTFE Vein PTFE
1 82% 82% 88% 81% 84% 77% 81% 80%
2 79% 69% 78% 68% 81% 69% 77% 69%
3 70% 56% 76% 68% 77% 58% 76% 61%
4 61% 38% 76% 68% 75% 50% 76% 58%
5 76% 68% 74% 39% 76% 52%
PTFE, Polytetrafluoroethylene.
JOURNAL OF VASCULAR SURGERY
January 2002154 Klinkert et al
graft material in our institution for all patients needing an
above-knee bypass procedure. Polytetrafluoroethylene is an
acceptable alternative when the saphenous vein is not avail-
able.
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